Skip to main content

Nubeqa Disease Interactions

There are 2 disease interactions with Nubeqa (darolutamide).

Moderate

Darolutamide (applies to Nubeqa) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patients with moderate hepatic impairment (Child-Pugh Class B) have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild hepatic impairment. The effect of severe hepatic impairment (Child-Pugh C) on darolutamide pharmacokinetics is unknown.

References

  1. "Product Information. Nubeqa (darolutamide)." Bayer HealthCare Pharmaceuticals Inc. (2019):
Moderate

Darolutamide (applies to Nubeqa) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2) who are not receiving hemodialysis have a higher exposure to darolutamide and reduction of the dose is recommended (see manufacturer package insert for recommended dose). No dose reduction is needed for patients with mild or moderate renal impairment. The effect of end stage renal disease (eGFR <15 mL/min/1.73 m2) on darolutamide pharmacokinetics is unknown.

References

  1. "Product Information. Adakveo (crizanlizumab)." Novartis Pharmaceuticals (2019):

Nubeqa drug interactions

There are 269 drug interactions with Nubeqa (darolutamide).

Nubeqa alcohol/food interactions

There is 1 alcohol/food interaction with Nubeqa (darolutamide).


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.